Zoic Capital
Zoic Capital is a venture capital firm established in 2017, located in Bellevue, Washington, with an additional office in Tampa, Florida. The firm specializes in early-stage investments focused on healthcare innovations that lie at the intersection of life sciences and medical technology. Zoic Capital seeks to identify promising scientific advancements that offer broad intellectual property potential and commercial readiness. The firm invests in technologies that support both the development of medical products and the delivery of care. By combining qualitative insights with quantitative analysis, Zoic Capital aims to make informed investment decisions. Additionally, it employs a milestone-based investment approach, crafting unique deal structures tailored to each portfolio company to foster ongoing momentum and success. With a commitment to mentoring, Zoic Capital leverages its expertise and network to help transform research into impactful, market-ready products.
Top Stages
11 past transactions
Trio Labs
Series A in 2024
Trio Labs is a digital manufacturing technology company specializing in high-volume precision metal and ceramic 3D printing. Founded in 2015 and based in Durham, North Carolina, the company aims to transform the manufacturing landscape by eliminating the costs associated with tooling while enhancing the throughput of traditional high-volume production processes. Trio Labs' innovative technology enables engineers to achieve precision comparable to existing systems, allowing for the affordable production of metals and ceramics at increased volumes and speeds.
ProbiusDx
Series B in 2023
ProbiusDx Inc. is a manufacturer of portable diagnostic devices that utilize an electronic sensing platform to analyze multiple target proteins in real time. Founded in 2015 and headquartered in El Cerrito, California, the company focuses on providing diagnostic technology for the detection and monitoring of blood concentrations. This innovative approach allows healthcare professionals to make informed decisions regarding appropriate therapies for patients in critical care settings. ProbiusDx aims to enhance patient outcomes through its advanced diagnostic solutions.
Chromatan
Seed Round in 2023
ChromaTan Inc. is a biotechnology company based in Lower Gwynedd, Pennsylvania, that specializes in the development of continuous countercurrent tangential chromatography (CCTC) technology for the purification of monoclonal antibodies and proteins. Founded in 2007, ChromaTan addresses a significant bottleneck in therapeutic protein production by providing an innovative, column-free, continuous, and single-use purification solution. This technology replaces traditional large-scale column chromatography processes, offering a cost-effective and scalable alternative for biotech and contract manufacturing companies. ChromaTan's CCTC platform has undergone extensive beta testing with major biotech firms, demonstrating a substantial increase in throughput while maintaining or improving product quality.
HDT Bio
Seed Round in 2022
HDT Bio is a clinical-stage biotechnology company specializing in the development of RNA-based vaccines and therapeutics aimed at combating infectious diseases and oncology. Utilizing its proprietary LION formulation technology, the company creates self-amplifying RNA vaccines and innate immune agonist therapeutics that enhance the stability and delivery of nucleic acids through various administration routes. HDT Bio's innovative approach addresses critical unmet medical needs by activating innate immunity, amplifying adaptive immune responses, and disrupting tumor tight junctions. The company's mission is to accelerate progress in immunotherapy, providing effective solutions not only in leading markets but also in low and middle-income countries, thereby contributing to the global fight against some of the most lethal infectious diseases and cancers.
ProbiusDx
Series A in 2020
ProbiusDx Inc. is a manufacturer of portable diagnostic devices that utilize an electronic sensing platform to analyze multiple target proteins in real time. Founded in 2015 and headquartered in El Cerrito, California, the company focuses on providing diagnostic technology for the detection and monitoring of blood concentrations. This innovative approach allows healthcare professionals to make informed decisions regarding appropriate therapies for patients in critical care settings. ProbiusDx aims to enhance patient outcomes through its advanced diagnostic solutions.
HDT Bio
Seed Round in 2020
HDT Bio is a clinical-stage biotechnology company specializing in the development of RNA-based vaccines and therapeutics aimed at combating infectious diseases and oncology. Utilizing its proprietary LION formulation technology, the company creates self-amplifying RNA vaccines and innate immune agonist therapeutics that enhance the stability and delivery of nucleic acids through various administration routes. HDT Bio's innovative approach addresses critical unmet medical needs by activating innate immunity, amplifying adaptive immune responses, and disrupting tumor tight junctions. The company's mission is to accelerate progress in immunotherapy, providing effective solutions not only in leading markets but also in low and middle-income countries, thereby contributing to the global fight against some of the most lethal infectious diseases and cancers.
BioROSA Technologies
Convertible Note in 2020
BioROSA Technologies Inc. is a biotechnology company focused on developing diagnostic tools for Autism Spectrum Disorders (ASD). Founded in 2018 and headquartered in Belmont, Massachusetts, the company specializes in creating biologically-based blood tests that assist clinicians in identifying individuals at risk for ASD. By utilizing machine learning to analyze biological data, BioROSA Technologies aims to provide reliable and accurate diagnoses, facilitating early detection and timely treatment. Additionally, the company's technology supports therapeutic trials by evaluating pharmacodynamics and patient stratification, thereby enhancing the overall standard of care for ASD.
ODS Medical
Seed Round in 2020
ODS Medical Inc. is a Montreal-based medical device company established in 2015, specializing in the design and manufacture of advanced diagnostic tools for cancer detection. The company's flagship product is an exclusive Raman spectroscopy system that enables real-time identification of tissue abnormalities across various clinical settings. By integrating innovative optical probes with sophisticated software powered by machine learning algorithms, ODS Medical aims to enhance the capabilities of physicians, allowing for critical decision-making with high sensitivity, specificity, and accuracy. Through its commitment to developing and commercializing cutting-edge technology, ODS Medical strives to revolutionize the diagnostic landscape in oncology.
Juno Diagnostics
Seed Round in 2019
Juno Diagnostics, Inc. is a health technology company based in San Diego, California, founded in 2017. The company specializes in developing cell-free DNA-based noninvasive prenatal testing, providing women and their healthcare providers with crucial genetic information. Juno Diagnostics aims to democratize access to high-value genetic data by creating simple and cost-effective testing devices that facilitate point-of-need genetic testing. Their innovative technology enhances sample collection and delivers high-quality test results without the need for traditional phlebotomy procedures, thus reducing costs and lead times associated with genetic testing. Additionally, Juno is involved in the development of genetic testing tools for applications in epigenetics, inherited diseases, and cancer diagnostics.
Optina Diagnostics
Seed Round in 2018
Optina Diagnostics Inc. is a Canadian company focused on developing innovative technology for the early detection of Alzheimer’s disease through hyperspectral imaging of the eye. Founded in 2010 and headquartered in Montréal, the company employs advanced retinal imaging and artificial intelligence to provide non-invasive diagnostic tests for under-diagnosed diseases. Optina Diagnostics' retinal imaging test identifies key patient features that assist healthcare professionals in evaluating health status and disease risk, enabling timely and appropriate care. The company's imaging systems not only facilitate the detection of Alzheimer's-related biomarkers, such as beta-amyloid plaques, but also address other conditions like age-related macular degeneration and diabetic retinopathy. By enhancing brain health assessment, Optina Diagnostics aims to deliver critical information early in the disease progression, ultimately improving patient outcomes.
InnoVein
Venture Round in 2018
InnoVein, Inc. is a medical device company established in 2015 and based in San Carlos, California. The company specializes in developing implantable valves designed to regulate blood flow in the veins, particularly for elderly patients suffering from venous insufficiency disease. InnoVein aims to address the challenges associated with this condition through innovative cardiac and arterial solutions, contributing to improved health outcomes for affected individuals.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.